Real-world effectiveness of pneumococcal vaccination in older adults: Cohort study using the UK Clinical Practice Research Datalink.

Adam J Streeter Lauren R RodgersJane MasoliNan X LinAlessandro BléWillie HamiltonWilliam E Henley

Published in: PloS one (2022)

PPV23 is moderately effective at reducing CAP among UK patients aged≥65y, in the two years after vaccination. Vaccine effectiveness is maintained, and may increase, in the oldest age groups in step with increasing susceptibility to CAP.

Keyphrases

randomized controlled trial
clinical practice
newly diagnosed
ejection fraction
cross sectional
physical activity
patient reported outcomes